La Jolla Pharmaceutical Company

NASDAQ: LJPC
$4.27
-$0.05 (-1.2%)
Real time price as of July 13, 2020 3:14 pm EDT
The analysts at SunTrust Robinson Humphrey put together a big list stocks ideas that they feel will outperform into year-end 2019. That list includes these five health care stocks with sizable upside.
These five stocks trading under the $10 level have big upside to the analysts' price targets and they are covered with Buy ratings at major Wall Street firms.
We screened our 24/7 Wall St. research database and found five biotech stocks trading under the $10 level that could provide investors with some solid upside potential.
PG&E, La Jolla Pharmaceuticals, AxoGen, and Maxar Technologies all posted new 52-week lows Tuesday.
Weight Watchers, Adient, AxoGen, and La Jolla Pharmaceuticals all posted new 52-week lows Monday.
La Jolla Pharmaceutical and Sarepta Therapeutics are among seven biotech stocks that have seen some notable insider trading recently.
The top analyst upgrades, downgrades and other research calls from Monday include American Express, Cisco, First Solar, Goldman Sachs, Nasdaq, Shopify, SunPower and Workday.
This year is shaping up to be a stellar one for biotech. Investors are looking for growth and upside, and that can drive the interest in biotechs ever higher.
We screened our 24/7 Wall St. research database for hot biotech ideas and found four companies that are offering big upside for aggressive accounts. All are rated Buy and have the potential to...
There can be some big biotech winners in 2018, given the changing landscape, and any of these 12 could be one.
These two biotech and two tech stocks not only have big upside potential, but they are priced right for investors looking for good entry points.
The top analyst upgrades, downgrades and other research calls from Wednesday include Blackstone, Ciena, Merck, Tempur Sealy and Universal Display.
For really the first time this year, we saw the pace of insider buying jump, and that may signal that while the rally could still have some legs, things are finally calming down some.
La Jolla Pharmaceutical saw its shares skyrocket on Monday after top-line results from its late-stage study of patients with catecholamine resistant hypotension.
In a new report, SunTrust Robinson Humphrey analysts are focused on upcoming catalysts for biotech stocks in their coverage universe.